Scientists at The Scripps Research Institute (TSRI) have reported successful preclinical tests of a new vaccine against heroin. The vaccine targets heroin and its psychoactive breakdown products in the bloodstream, preventing them from reaching the brain.
"Heroin-addicted rats deprived of the drug will normally resume using it compulsively if they regain access, but our vaccine stops this from happening," said George F. Koob, who chairs TSRI's addiction research group, the Committee on the Neurobiology of Addictive Disorders. If the vaccine works as well in human trials, it could become a standard part of therapy for heroin addiction, which is estimated to affect more than 10 million people worldwide.
Koob, TSRI Professor Kim Janda, and their laboratories led the study, which appears during the week of May 6, 2013 in the Early Edition of the Proceedings of the National Academy of Sciences.
The heroin vaccine is one of several vaccines against drugs of abuse that have been developed since the 1990s by scientists at TSRI and other institutions.
The structures of common drug molecules are too small and simple to stimulate the immune system sufficiently on their own, but vaccine designers have overcome this hurdle by affixing key fragments of drug molecules to larger, more immune-provoking carrier proteins. Vaccines against cocaine and nicotine that have been designed this way are now in clinical testing, and a methamphetamine vaccine is nearing readiness for such tests.
Designing an effective vaccine against heroin has been particularly challenging because the drug breaks down rapidly in the bloodstream after injection. "Heroin is metabolized very quickly to another compound called 6-acetylmorphine, which crosses into the brain and accounts for much of heroin's effect," said Janda, who is TSRI's Ely R. Callaway, Jr. Chair in Chemistry and whose laboratory initially developed the vaccine three years ago.
Janda and his team therefore designed the heroin vaccine to elicit antibodies against not only heroin, but also 6-acetylmorphine and morphine. "The vaccine effectively tracks the drug as it is metabolized, keeping the active breakdown products out of the brain, and that, I think, explains its success," Janda said.
Initial tests, reported in 2011, showed the vaccine could block some of the acute effects of heroin, such as obstructing pain. In the new study, the Koob laboratory put the vaccine through more rigorous tests.
"We gave the vaccine to rats that had already been exposed to heroin, a situation obviously relevant to a human clinical situation," said postdoctoral research associate Joel Schlosburg, who was first author of the study.
In one test, rats trained to press a lever three times to get an infusion of heroin later went through sessions of "extinction training," in which lever presses no longer produced infusions. Among rats that had not received the heroin vaccine, a single infusion of heroin could immediately reinstate a rat's drug-seeking lever-pressing behavior—just as human users relapse to drug-seeking after re-exposure to heroin. However, rats that had been vaccinated failed to resume their heroin-seeking lever-presses.
In an even more challenging test, rats that had become severely addicted to heroin and were taking it compulsively in escalating amounts—amounts that would have been lethal to drug-naïve rats—were forced to abstain for 30 days before being given renewed access. In rats that had received a dummy vaccine, intake resumed and they re-escalated, taking the drug compulsively. But in the heroin-vaccinated rats, intake failed to escalate and compulsive drug taking did not redevelop.
"Basically we were able to stop them from going through that cycle of taking more and more heroin," said Schlosburg. "And that was with the vaccine alone; ideally for human patients, the vaccine would be given with other treatments."
Keeping the Drug Out of the Brain
The researchers confirmed that the vaccine sequesters heroin and 6-acetylmorphine in the bloodstream, keeping it out of the brain. The vaccine did not block the effects of methadone, buprenorphine and other opioid-receptor-targeting drugs that are commonly used in addiction therapy. "It doesn't affect the opioid system per se, so in principle you could give this vaccine to heroin-dependent people and continue to treat them with standard therapies, too," Schlosburg said. "Opioid painkillers such as codeine or oxycodone also would continue to work."
Janda notes that in some other trials of drug vaccines and therapies, rats have been known to compensate for the reduced drug effects by doubling or tripling their intake. "But with this heroin vaccine, they don't try to load up more heroin to beat the vaccine—which is pretty impressive," he said.
Janda expects to make minor changes to the heroin vaccine for trials in humans, but said, "We think it's now about as good as it can be." He is now actively seeking a pharmaceutical company partner to sponsor those clinical trials and, assuming that they go well, to eventually market the vaccine.
Scripps Research Institute: http://www.scripps.edu
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Doctors have used perfect replicas of childrens' hearts to uncover and repair hidden defects
An experiment testing people’s altruism in the face of electric shocks is clear on one thing: we are drawn to these little blasts
Researchers gear up tests in West Africa to see whether blood from Ebola survivors can help people who are sick with the disease. This is part of a broader effort to test therapies in West Africa.
The virus's foray into Europe coincides with peak production of Christmas turkeys, the poultry species most vulnerable to bird flu
A novel kind of nanoparticle could lead to more effective cancer treatments.Patients and doctors often don’t know if surgery to remove cancerous tissue was successful until scans are performed months later. A new kind of nanoparticle could show patients if they’re in the clear much earlier.
One challenge in evaluating the effectiveness of different medical procedures, is that patients behave differently after different procedures. Is this true for patients getting heart surgery?
It is only in the aftermath of treatment that survivors discern that their adrenalin alone wont fuel the rest of their recovery. For many, surviving cancer is followed by even more hardship
Just down the road from Facebook and Google, Dr. Phil Wagner runs a laboratory dedicated to optimizing the performance of some of the world's top athletes. At Sparta Performance Science in Menlo Park, California, Wagner and his team bring the spirit of Silicon Valley to bear on the athletic world, helping athletes find the tiny advantages that add to championships. Join us for a trip inside the lab to see where sports meets science.
Pieter Cohen, an internist in Massachusetts, got interested in dietary supplements several years ago, when some of his …
The risk of overdiagnosis and false positives means the UK may be barking up the wrong tree in trialling a wider target age range for breast screening